Income Statement Virax Biolabs Group Limited
Equities
VRAX
KYG9495L1251
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1041 USD | -22.83% |
|
-40.17% | -69.90% |
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
Revenues | 124K | - | 8.56K | 156K | 6.33K | |
Total Revenues | 124K | - | 8.56K | 156K | 6.33K | |
Cost of Goods Sold, Total | 133K | - | 9.93K | 106K | 59.4K | |
Gross Profit | -9.43K | - | -1.36K | 50.59K | -53.07K | |
Selling General & Admin Expenses, Total | 515K | 1.3M | 5.33M | 4.59M | 4.33M | |
R&D Expenses | 120K | 434K | 397K | 1.56M | 1.78M | |
Other Operating Expenses, Total | 635K | 1.73M | 5.73M | 6.16M | 6.11M | |
Operating Income | -645K | -1.73M | -5.73M | -6.11M | -6.16M | |
Interest Expense, Total | -28.64K | -15.44K | -15.47K | -26.88K | -58.18K | |
Net Interest Expenses | -28.64K | -15.44K | -15.47K | -26.88K | -58.18K | |
Other Non Operating Income (Expenses) | 266 | -753 | 290K | -17.73K | 17.18K | |
EBT, Excl. Unusual Items | -673K | -1.75M | -5.46M | -6.15M | -6.2M | |
Asset Writedown | - | - | - | -390K | - | |
Legal Settlements | - | - | - | -210K | - | |
Other Unusual Items | - | - | - | 12.46K | - | |
EBT, Incl. Unusual Items | -673K | -1.75M | -5.46M | -6.74M | -6.2M | |
Income Tax Expense | - | - | - | - | -137K | |
Earnings From Continuing Operations | -673K | -1.75M | -5.46M | -6.74M | -6.07M | |
Net Income to Company | -673K | -1.75M | -5.46M | -6.74M | -6.07M | |
Minority Interest | 21.93K | 41.04K | 269 | 5.58K | 5.98K | |
Net Income - (IS) | -651K | -1.71M | -5.46M | -6.73M | -6.06M | |
Net Income to Common Incl Extra Items | -651K | -1.71M | -5.46M | -6.73M | -6.06M | |
Net Income to Common Excl. Extra Items | -651K | -1.71M | -5.46M | -6.73M | -6.06M | |
Per Share Items | ||||||
Net EPS - Basic | -2.71 | -1.79 | -5.13 | -3.36 | -1.62 | |
Basic EPS - Continuing Operations | -2.71 | -1.79 | -5.13 | -3.36 | -1.62 | |
Basic Weighted Average Shares Outstanding | 240K | 956K | 1.06M | 2.01M | 3.73M | |
Net EPS - Diluted | -2.71 | -1.79 | -5.13 | -3.36 | -1.62 | |
Diluted EPS - Continuing Operations | -2.71 | -1.79 | -5.13 | -3.36 | -1.62 | |
Diluted Weighted Average Shares Outstanding | 240K | 956K | 1.06M | 2.01M | 3.73M | |
Normalized Basic EPS | -1.66 | -1.1 | -3.21 | -1.91 | -1.04 | |
Normalized Diluted EPS | -1.66 | -1.1 | -3.21 | -1.91 | -1.04 | |
Supplemental Items | ||||||
EBITDA | - | - | - | -6.05M | -5.91M | |
EBITA | -645K | -1.73M | -5.73M | -6.11M | -6.16M | |
EBIT | -645K | -1.73M | -5.73M | -6.11M | -6.16M | |
Total Revenues (As Reported) | 124K | - | - | - | - | |
Effective Tax Rate - (Ratio) | - | - | - | - | 2.2 | |
Normalized Net Income | -399K | -1.05M | -3.41M | -3.84M | -3.87M | |
Interest on Long-Term Debt | - | - | - | 26.35K | 45.6K | |
Supplemental Operating Expense Items | ||||||
Selling and Marketing Expenses | 57.2K | 13.82K | 26.62K | - | - | |
General and Administrative Expenses | 458K | 1.29M | 5.31M | 4.59M | 4.33M | |
Research And Development Expense From Footnotes | 120K | 434K | 397K | 1.56M | 1.78M | |
Net Rental Expense, Total | 32.14K | - | - | - | - | |
Imputed Operating Lease Interest Expense | 15.81K | - | - | - | - | |
Imputed Operating Lease Depreciation | 16.32K | - | - | - | - | |
Stock-Based Comp., G&A Exp. (Total) | - | - | 1.73M | - | 630K | |
Stock-Based Comp., Other (Total) | - | - | 20K | 1.01M | - | |
Total Stock-Based Compensation | - | - | 1.75M | 1.01M | 630K |
- Stock Market
- Equities
- VRAX Stock
- Financials Virax Biolabs Group Limited
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition